HPV infections and vaccine attitudes in Slovenian women
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This observational study looks at HPV infections and women's views about the HPV vaccine in Slovenia. It aims to understand the characteristics of HPV infections and attitudes toward vaccination after the vaccine became available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman living in Slovenia.
- You have had a regular cervical smear (a test for cells from your cervix) as part of the national screening program, or a follow-up smear after an abnormal result or treatment.
- You are not pregnant at the time of the gynecological exam.
- You do not have menstrual bleeding, vaginal or cervical inflammation, or any other medical condition that would prevent the smear from being taken.
- You have not had your cervix removed (hysterectomy) and have not already had a smear taken for this study.
- You are not allergic to any ingredients in the HPV vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women diagnosed with certain types of cervical cancer between 2019 and 2024 to help improve prevention. By reviewing medical records, researchers hope to find better ways to catch and prevent cervical cancer.
This trial tests if a single dose of a locally made HPV vaccine (CERVAVAC) works as well as a single dose of the standard Gardasil vaccine. It is for girls and young women aged 9 to 20, and boys aged 9 to 14, in Zambia. The goal is to prevent HPV infection, which can cause cervical cancer.
This study looks at ways to improve cervical cancer prevention for women in Scotland who face extra challenges, such as addiction, homelessness, prison, or sex work. It includes a vaccination and screening part, plus an interview to hear your views.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This study tests giving the HPV vaccine along with HPV screening to quickly reduce HPV infection and cervical cancer. It is for women aged 23-29 in Rwanda who choose to join.
Hear when a new Cervical Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.